RAC1 and cancer: In parallel, as our studies highlighted a prominent role of the Rho GTPase Rac1 on 5-FU-resistance modulation, we decided to explore the effects of 1A-116, a novel Rac1 inhibitor previously reported to be promising to treat other cancer types [46,53,54,55].